Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.

ABSTRACT:

Introduction

Perioperative dosing recommendations vary across Nordic haemophilia treatment centres (HTCs) for extended half-life (EHL) factor concentrates in haemophilia A/B (HA/HB) patients.

Aim

To summarise Nordic real-world surgical experiences with EHL recombinant factor VIII/IX Fc (rFVIIIFc/rFIXFc) fusion proteins using retrospective data from clinical records at four HTCs in Finland, Sweden and Norway.

Methods

Factor dosing and surgical outcomes were recorded from HA/HB patients who underwent surgery and were treated with rFVIIIFc/rFIXFc. Perioperative factor dosing regimens were clinician-determined based on local practises.

Results

Twenty five surgeries were performed on 20 patients, all covered by bolus injections except one minor HA surgery; eight min

SUBMITTER: Lehtinen AE 

PROVIDER: S-EPMC9542088 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature